secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001213900-24-016715
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences exchanges $9M maturing notes for new 10% notes due 2025; conversion price adjustable
--------------------------------------------------------------------------------

- Exchanged $9M principal of 2% convertible notes due Feb 24, 2024 for new 10% notes due Feb 24, 2025.
- Conversion price initially $0.13/share, subject to quarterly decrease to equal VWAP; no additional consideration.
- Principal and interest on new notes payable in two equal semi-annual installments.
- Note holders joined Transfer Restriction and Voting Agreement, restricting resale and voting of conversion shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390024016715/0001213900-24-016715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390024016715/ea0200618-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-016715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer